STOCK TITAN

Hoth Therapeutics Inc Stock Price, News & Analysis

HOTH Nasdaq

Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.

Hoth Therapeutics Inc (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company advancing novel therapies for dermatological conditions, oncology targets, and neurodegenerative disorders. This news hub provides investors and researchers with timely updates on clinical trial progress, regulatory milestones, and strategic partnerships central to evaluating Hoth’s therapeutic pipeline.

Discover authoritative coverage of Hoth’s innovative platforms including the BioLexa antimicrobial system and HT-ALZ for Alzheimer’s research. Our curated news collection features press releases on FDA designations, preclinical data disclosures, and licensing agreements with academic institutions like George Washington University and North Carolina State University.

Key updates include developments across three core areas: dermatology (eczema/chronic wound treatments), oncology (HT-KIT for mast cell cancers), and neurology (neuroinflammation targeting). Each news item is verified for accuracy to support informed analysis of Hoth’s research trajectory and market position.

Bookmark this page for consolidated access to Hoth Therapeutics’ latest announcements, including earnings reports, intellectual property filings, and collaborative research initiatives. Regularly updated to serve as your primary resource for tracking this innovative biopharma’s progress in addressing unmet medical needs.

Rhea-AI Summary

Hoth Therapeutics (NASDAQ: HOTH) and Silo Pharma (NASDAQ: SILO) have formed a 50/50 joint venture to develop and commercialize a novel obesity treatment licensed from the U.S. Department of Veterans Affairs. The therapy is based on Glial Cell Line-Derived Neurotrophic Factor (GDNF), targeting obesity and non-alcoholic fatty liver disease (NAFLD).

The technology, protected under U.S. Patent No. 10,052,362, aims to address a $100B+ market with potential applications for type 2 diabetes and central obesity. The partnership combines the VA's clinical infrastructure, Hoth's regulatory expertise, and Silo's translational capabilities to develop this first-in-class treatment targeting the neuroinflammatory root of obesity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.03%
Tags
none
-
Rhea-AI Summary

Hoth Therapeutics (NASDAQ: HOTH) announced breakthrough interim results for its HT-001 Phase 2a clinical trial, achieving a 100% response rate in at least one primary endpoint for treating EGFR inhibitor-induced skin toxicities. The trial demonstrated that over 65% of patients reported reduced pain and itching, with no patients requiring dose reduction or discontinuation of their cancer treatment.

HT-001, a once-daily topical gel containing an FDA-approved NK1 receptor antagonist, targets inflammatory pathways triggered by EGFR inhibition. The therapy showed significant efficacy in preclinical studies and is being developed under the 505(b)(2) regulatory pathway, positioning it to potentially become the first FDA-approved treatment specifically for EGFRI-related skin toxicities, which affect up to 90% of cancer patients receiving EGFR inhibitors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
none
-
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) announced a virtual Key Opinion Leader (KOL) event scheduled for June 24, 2025, at 3:30PM EST, focusing on their novel therapy HT-001. The event will feature expert insights from Dr. Jonathan Hale Zippin and Dr. Adam Friedman, who will discuss interim results from the ongoing Phase 2 trial of HT-001, a topical treatment designed for EGFR inhibitor-induced skin toxicities in cancer patients. The specialists will explore how this innovative therapy could potentially transform supportive care standards in oncology. The virtual event will be accessible via Zoom.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
conferences
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) has successfully regained compliance with Nasdaq's minimum bid price requirement after its common stock maintained a closing price above $1.00 for 10 consecutive trading sessions from June 4-17, 2025. This achievement resolves the previous listing compliance issue, as confirmed by formal notice from the Nasdaq Listing Qualifications Department on June 18, 2025. CEO Robb Knie emphasized this milestone's significance, expressing confidence in the company's strategy and pipeline. The clinical-stage biopharmaceutical company is now positioned to focus on advancing its therapeutic portfolio across inflammatory diseases, oncology, and rare diseases, with expectations for key developments throughout 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
none
-
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) reported positive preclinical safety data for its cancer therapeutic candidate HT-KIT. The multi-dose study demonstrated dose-dependent liver activity with no observable toxicity, marking a significant milestone toward clinical trials. Key findings showed liver weight increased from 1.11g to 1.32g across dosing from 0 to 3.0 mg/kg, with no adverse effects on kidney, spleen, thymus, or other organs. The study validated HT-KIT's safety profile in vivo with no visible lesions or gross pathology. CEO Robb Knie emphasized these results support their advancement toward GLP studies and IND submission, highlighting the clear biological response without organ damage as a positive indicator for the drug's development pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
-
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, announced that CEO Robb Knie will attend the BIO International Convention in Boston from June 16-19, 2025. The event is recognized as the largest biotechnology convention globally, bringing together approximately 20,000 industry leaders from the biotech ecosystem. The BIO International Convention serves as a significant platform for networking and industry insights in the biotechnology sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) has secured Japanese Patent No. 7677628 for its HT-KIT platform technology, providing protection until August 27, 2039. The patent, titled "Targeting KIT with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells," covers their innovative approach using splice-switching oligonucleotides to disrupt KIT gene expression in mast cells. This technology targets conditions ranging from chronic hives to rare cancers. CEO Robb Knie highlighted the strategic importance of securing IP protection in Japan's pharmaceutical market, indicating potential licensing opportunities across Asia. The company is actively seeking strategic global partners for co-development and commercialization of the HT-KIT platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.58%
Tags
none
-
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) has announced a significant advancement for its lead drug HT-001 by engaging Premier Research to support an Expanded Access Program (EAP) application. The initiative aims to provide compassionate access to HT-001 for cancer patients experiencing skin toxicities from EGFR inhibitor therapies. The company reports encouraging signals from their Phase 2a open-label cohort study. HT-001 addresses a significant market opportunity, with over 100,000 cancer patients annually receiving EGFR inhibitors, most of whom experience skin toxicities with no currently approved targeted treatments. The EAP status could accelerate commercialization while generating valuable real-world data. This strategic move positions Hoth to capture a growing segment in oncology supportive care while demonstrating their commitment to patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags
none
-
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) announced a KOL event to showcase HT-001, their novel topical treatment for skin toxicities caused by EGFR inhibitor cancer therapies. The event, scheduled for June 24, 2025, will feature experts Dr. Jonathan Zippin and Dr. Adam Friedman discussing preliminary Phase 2a trial results and a case study. HT-001 aims to address a significant market need, as the chemotherapy drug market is projected to grow from $10.87B (2024) to $18.35B (2031). The company recently received a USPTO Filing Receipt for HT-001's formulation, strengthening its IP portfolio. CEO Robb Knie emphasized HT-001's potential as a first-of-its-kind treatment for cancer patients suffering from EGFR therapy-related skin toxicities, which often force patients to reduce or discontinue essential cancer treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.92%
Tags
none
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) has announced promising preclinical results for HT-KIT, its antisense oligonucleotide therapy targeting KIT-driven cancers. The treatment demonstrated over 80% reduction in KIT expression in cancer cell lines and showed significant tumor growth inhibition in GIST and mast cell tumor models. Key highlights include no observable off-target toxicity in vital organs and a favorable safety profile. HT-KIT represents a novel approach to treating KIT-mutated cancers at the genetic level, potentially offering advantages over current tyrosine kinase inhibitors by avoiding resistance mechanisms. The company plans to file an IND application with the FDA in early 2026, followed by Phase 1 trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags

FAQ

What is the current stock price of Hoth Therapeutics (HOTH)?

The current stock price of Hoth Therapeutics (HOTH) is $1.44 as of July 11, 2025.

What is the market cap of Hoth Therapeutics (HOTH)?

The market cap of Hoth Therapeutics (HOTH) is approximately 16.0M.
Hoth Therapeutics Inc

Nasdaq:HOTH

HOTH Rankings

HOTH Stock Data

15.98M
13.14M
0.93%
3.53%
1.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK